Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Public ClinicalTrials.gov record NCT03810313. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
Study identification
- NCT ID
- NCT03810313
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 493 participants
Conditions and interventions
Conditions
Interventions
- Brolucizumab 6 mg Drug
- Aflibercept 2 mg Drug
- Sham injection Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2019
- Primary completion
- Jul 25, 2021
- Completion
- Jul 25, 2021
- Last update posted
- Jan 29, 2023
2019 – 2021
United States locations
- U.S. sites
- 30
- U.S. states
- 16
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85020 | — |
| Novartis Investigative Site | La Jolla | California | 92093 | — |
| Novartis Investigative Site | Mountain View | California | 94040 | — |
| Novartis Investigative Site | Santa Barbara | California | 93103 | — |
| Novartis Investigative Site | Colorado Springs | Colorado | 80909 | — |
| Novartis Investigative Site | Fort Myers | Florida | 33912-7125 | — |
| Novartis Investigative Site | St. Petersburg | Florida | 33711 | — |
| Novartis Investigative Site | Indianapolis | Indiana | 46280 | — |
| Novartis Investigative Site | New Albany | Indiana | 47150 | — |
| Novartis Investigative Site | Leawood | Kansas | 66211 | — |
| Novartis Investigative Site | Lenexa | Kansas | 66215 | — |
| Novartis Investigative Site | Stoneham | Massachusetts | 02180 | — |
| Novartis Investigative Site | Minneapolis | Minnesota | 55435 | — |
| Novartis Investigative Site | Reno | Nevada | 89502 | — |
| Novartis Investigative Site | Bloomfield | New Jersey | 07003 | — |
| Novartis Investigative Site | Charlotte | North Carolina | 28210 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44122 | — |
| Novartis Investigative Site | Cleveland | Ohio | 44195 | — |
| Novartis Investigative Site | Monroeville | Pennsylvania | 15146 | — |
| Novartis Investigative Site | Memphis | Tennessee | 38119 | — |
| Novartis Investigative Site | Nashville | Tennessee | 37203 | — |
| Novartis Investigative Site | Abilene | Texas | 79606 | — |
| Novartis Investigative Site | Arlington | Texas | 76012 | — |
| Novartis Investigative Site | Austin | Texas | 78731 | — |
| Novartis Investigative Site | Austin | Texas | 78750 | — |
| Novartis Investigative Site | Bellaire | Texas | 77401 | — |
| Novartis Investigative Site | Houston | Texas | 77025 | — |
| Novartis Investigative Site | Houston | Texas | 77030 | — |
| Novartis Investigative Site | San Antonio | Texas | 78240 | — |
| Novartis Investigative Site | Madison | Wisconsin | 53705-3611 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03810313, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 29, 2023 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03810313 live on ClinicalTrials.gov.